- Home
- FT vs GNFT Comparison
FT vs GNFT Comparison
Compare FT & GNFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FT
- GNFT
- Stock Information
- Founded
- FT 1988
- GNFT 1999
- Country
- FT United States
- GNFT France
- Employees
- FT N/A
- GNFT N/A
- Industry
- FT Trusts Except Educational Religious and Charitable
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FT Finance
- GNFT Health Care
- Exchange
- FT Nasdaq
- GNFT Nasdaq
- Market Cap
- FT 192.5M
- GNFT 186.3M
- IPO Year
- FT N/A
- GNFT 2019
- Fundamental
- Price
- FT $7.72
- GNFT $3.75
- Analyst Decision
- FT
- GNFT Strong Buy
- Analyst Count
- FT 0
- GNFT 1
- Target Price
- FT N/A
- GNFT $13.00
- AVG Volume (30 Days)
- FT 63.0K
- GNFT 3.8K
- Earning Date
- FT 01-01-0001
- GNFT 04-24-2025
- Dividend Yield
- FT 7.85%
- GNFT N/A
- EPS Growth
- FT N/A
- GNFT N/A
- EPS
- FT N/A
- GNFT 0.03
- Revenue
- FT N/A
- GNFT $73,187,701.00
- Revenue This Year
- FT N/A
- GNFT $15.98
- Revenue Next Year
- FT N/A
- GNFT N/A
- P/E Ratio
- FT N/A
- GNFT $120.71
- Revenue Growth
- FT N/A
- GNFT 105.01
- 52 Week Low
- FT $5.97
- GNFT $2.55
- 52 Week High
- FT $7.23
- GNFT $6.42
- Technical
- Relative Strength Index (RSI)
- FT 61.92
- GNFT 44.52
- Support Level
- FT $7.45
- GNFT $3.44
- Resistance Level
- FT $7.77
- GNFT $3.81
- Average True Range (ATR)
- FT 0.09
- GNFT 0.17
- MACD
- FT 0.01
- GNFT -0.00
- Stochastic Oscillator
- FT 77.94
- GNFT 56.65
About FT Franklin Universal Trust
Franklin Universal Trust is a closed-end management investment company. Its primary investment objective is to provide high, current income consistent with the preservation of capital. Its secondary objective is the growth of income through dividend increases and capital appreciation. The fund invests in two asset classes being the high yield bonds and utility stocks.
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.